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A total of 42 patients (22 previously untreated and 20 previously treated) with GH deficiency were included in a Spanish multicentre trial of recombinant somatropin, 0.5 IU/kg/week. In previously untreated patients typical catch-up growth was observed and the height velocity increased from 3.3 +/- 0.6 cm/year to 9.8 +/- 2.4 cm/year during 1 year of therapy. In previously treated children, the height velocity was maintained (7.2 +/- 2.0 cm/year at the start and 7.9 +/- 1.6 cm/year after 1 year). No anti-GH antibodies were detected in previously untreated patients, and they disappeared from previously treated ones. No adverse reactions were reported.